Bioequivalence and comparative pharmacodynamics of insulin lispro 200 U/mL relative to insulin lispro (Humalog®) 100 U/mL

Lignende værker

• Bioequivalence of Ultra Rapid Lispro (URLi) U100 and U200 Formulations in Healthy Subjects
  af: Linnebjerg, Helle, et al.
  Udgivet: (2020)
• Anti-Insulin Antibodies and Adverse Events with Biosimilar Insulin Lispro Compared with Humalog Insulin Lispro in People with Diabetes
  af: Home, Philip, et al.
  Udgivet: (2018)
• Subcutaneous Injection Depth Does Not Affect the Pharmacokinetics or Glucodynamics of Insulin Lispro in Normal Weight or Healthy Obese Subjects
  af: de la Peña, Amparo, et al.
  Udgivet: (2015)
• In Silico Head-to-Head Comparison of Insulin Glargine 300 U/mL and Insulin Degludec 100 U/mL in Type 1 Diabetes
  af: Schiavon, Michele, et al.
  Udgivet: (2020)
• Glycaemic control and hypoglycaemia risk with insulin glargine 300 U/mL and insulin degludec 100 U/mL in older participants in the BRIGHT trial
  af: Bolli, Geremia B., et al.
  Udgivet: (2021)